CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer.
CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer.
复制标题
在ER阴性乳腺癌中，CXCL9是一个潜在的免疫浸润性生物标志物，与良好的预后相关。
DOI：
10.3389/fonc.2021.710286
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Lin HY
中科院分区：
文献类型：
--
作者：
Liang YK;Deng ZK;Chen MT;Qiu SQ;Xiao YS;Qi YZ;Xie Q;Wang ZH;Jia SC;Zeng D;Lin HY
据报道，趋化因子CXCL 9（C-X-C基序趋化因子配体9）是免疫检查点阻断后抗肿瘤免疫应答所需的。在这项研究中，我们试图根据乳腺癌（BC）患者的免疫反应来研究CXCL 9的潜在价值。利用各种开源数据库和在线工具探讨CXCL 9在BC中的表达特征和预后意义及其与免疫相关生物标志物的相关性，随后通过免疫组化实验进行验证。研究发现，BC中CXCL 9 mRNA水平显著高于正常组织，并且与ER阴性肿瘤患者的更好生存结局相关。此外，CXCL 9与免疫细胞浸润和免疫相关生物标志物（包括CTLA 4、GZMB、LAG 3、PDCD 1和HAVCR 2）显著相关。最后，我们对乳腺癌组织样本进行免疫组化，观察到CXCL 9在ER阴性亚组中高表达，并与免疫相关因子LAG 3、PD 1、PDL 1和CTLA 4呈不同程度的正相关。这些发现表明CXCL 9是预测ER阴性乳腺癌中免疫浸润状态的潜在生物标志物。
The chemokine CXCL9 (C-X-C motif chemokine ligand 9) has been reported to be required for antitumour immune responses following immune checkpoint blockade. In this study, we sought to investigate the potential value of CXCL9 according to immune responses in patients with breast cancer (BC). A variety of open-source databases and online tools were used to explore the expression features and prognostic significance of CXCL9 in BC and its correlation with immune-related biomarkers followed by subsequent verification with immunohistochemistry experiments. The CXCL9 mRNA level was found to be significantly higher in BC than in normal tissue and was associated with better survival outcomes in patients with ER-negative tumours. Moreover, CXCL9 is significantly correlated with immune cell infiltration and immune-related biomarkers, including CTLA4, GZMB, LAG3, PDCD1 and HAVCR2. Finally, we performed immunohistochemistry with breast cancer tissue samples and observed that CXCL9 is highly expressed in the ER-negative subgroup and positively correlated with the immune-related factors LAG3, PD1, PDL1 and CTLA4 to varying degrees. These findings suggest that CXCL9 is an underlying biomarker for predicting the status of immune infiltration in ER-negative breast cancer.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
64.8
作者：
Curtis, Christina;Shah, Sohrab P.;Chin, Suet-Feung;Turashvili, Gulisa;Rueda, Oscar M.;Dunning, Mark J.;Speed, Doug;Lynch, Andy G.;Samarajiwa, Shamith;Yuan, Yinyin;Graef, Stefan;Ha, Gavin;Haffari, Gholamreza;Bashashati, Ali;Russell, Roslin;McKinney, Steven;Langerod, Anita;Green, Andrew;Provenzano, Elena;Wishart, Gordon;Pinder, Sarah;Watson, Peter;Markowetz, Florian;Murphy, Leigh;Ellis, Ian;Purushotham, Arnie;Borresen-Dale, Anne-Lise;Brenton, James D.;Tavare, Simon;Caldas, Carlos;Aparicio, Samuel
通讯作者：
Aparicio, Samuel
影响因子：
28.4
作者：
Adams S;Gatti-Mays ME;Kalinsky K;Korde LA;Sharon E;Amiri-Kordestani L;Bear H;McArthur HL;Frank E;Perlmutter J;Page DB;Vincent B;Hayes JF;Gulley JL;Litton JK;Hortobagyi GN;Chia S;Krop I;White J;Sparano J;Disis ML;Mittendorf EA
通讯作者：
Mittendorf EA
DOI：
10.1186/bcr3115
发表时间：
2012-02-14
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Bronger H;Kraeft S;Schwarz-Boeger U;Cerny C;Stöckel A;Avril S;Kiechle M;Schmitt M
通讯作者：
Schmitt M
影响因子：
7.2
作者：
Lieber S;Reinartz S;Raifer H;Finkernagel F;Dreyer T;Bronger H;Jansen JM;Wagner U;Worzfeld T;Müller R;Huber M
通讯作者：
Huber M